Saturday June 8, 13:45–15:45. Room B-Hall E, Moscone Center, San Francisco, California
- Renal effects of GLP-1 receptor agonists: from basic mechanisms to clinical data. Julie A. Lovshin, MD, PhD
- Cardiovascular effects of GLP-1 receptor agonists: From basic mechanisms to clinical data. Jens J. Holst, MD, DMSc
- Renal effects of SGLT2 Inhibitors: From basic mechanisms to clinical data. David C. Wheeler, MD
- Cardiovascular effects of SGLT2 inhibitors: From basic mechanisms to clinical data. Javed Butler, MD, MPH, MBA
This session links directly to the recent ask the expert videos we produced with Dr Katherine Tuttle [Nephrologist and Endocrinologist], regarding the impact of renal impairment on cardiovascular disease. We should really be discussing "cardio-renal disease" rather than "cardiovascular disease".
More on this topic
- News story | Canagliflozin may offer renal protection in people with type 2 diabetes and CKD
- Video commentary | Lead investigator Vlado Perkovic talks about the main findings from the CREDENCE trial (6:51)
- Video commentary | John Wilding discusses how the CREDENCE trial findings may impact the treatment of people with type 2 diabetes and chronic kidney disease (3:31)
- Practical management | Primary care practitioner Kevin Fernando applies the latest ADA/EASD guidelines to a case study of high CV risk